About Us | FAQ | Contact | Advertise  | RSS Feed
Subscribe to this feed
ADVANCE for Imaging & Radiation Oncology RSS Feed
Or click on the RSS link below: http://imaging-radiation-oncology.advanceweb.com/Editorial/Content/rssfeed.rss
Search
Login | Sign Up

Current Issue

Subscriptions are FREE to qualified imaging and radiation oncology professionals.

Log in to View Digital Subscribe

References

Breaking Down Brachytherapy

Louis Potters, MD, FACR, references his curriculum vitae in our brachytherapy round table.


Print ArticleEmail Article
Share
reddit Newsvine Del.icio.us Digg
Yahoo! Buzz LinkedIn StumbleUpon Google Bookmarks Mixx

CURRICULUM VITAE (abbreviated)

Louis Potters, MD, FACR, Department of Radiation Oncology, Long Island Jewish Medical Center, New Hyde Park, N.Y.

Publications: Primary Papers (Peer Reviewed)

  1. Austin, J.P., Aziz, H., Potters, L., Thelmo, W., et al. (1990). Diminished survival of young blacks with adenocarcinoma of the prostate. Am. J of Clinical Oncology (CCT), 13, 465-9.
  2. Choi, K.N., Aziz, H., Potters, L., Stark, R., et al. (1991). Locally advanced paranasal sinus and nasopharyngeal complex cancers treated with hyperfractionated radiation and concomitant infusion cisplatinum. Cancer, 67, 2748-52.
  3. Rush, S., Lovecchio, J., Gal, D., DeMarco, L., et al. (1992). Comrehensive management including interstial brachytherapy for locally advanced or recurrent gynecologic malignancies. Gynecologic Oncology, 46, 322-5.
  4. Austin, J.P., Aziz, H., Potters, L., Oshelfski, J. (1994). Effects of pretreatment TURP on survival in prostatic carcinoma. J Natl Med Assoc, 86, 833-8.
  5. Rush, S., Gal, D., Potters, L., Bosworth, J., et al. (1995). Pelvic control following external beam radiation for surgical stage I endometrial cancer. Int J of Rad Onc Bio and Phys, 33, 851-4.
  6. Gal, D., Rush, S., Lovecchio, J., Potters, L., et al. (1996). Lymphovascular space involement; a prognostic indicator in patients with surgical stage I endometrial adenocarcinoma with postoperative radiation. Int J of Gyn Cancer, 6, 135-9.
  7. Cha, C., Potters, L., Ashley, R., Freeman, K., et al. (1999). Isotope selection for patients undergoing prostate brachytherapy. Int J Rad Onc Bio Phys, 45, 391-5.
  8. Gelblum, D.Y., Potters, L., Ashley, R., Waldbaum, R., et al. (1999). Urinary morbidity following ultrasound guided transperineal prostate seed implantation. Int J Rad Onc Bio Phys, 45, 59-67.
  9. Potters, L., Cha, C., Oshinky, G., Venkatraman, E., et al. (1999). Risk profiles to predict PSA relapse free survival for patients undergoing permanent prostate brachytherapy. The Cancer J from Scientific Am, 5, 301-6.
  10. Potters, L., Torre, T., Ashley, R., Leibel, S. (2000). Efficacy of Neoadjuvant Androgen Deprivation in Patients undergoing Prostate Brachytherapy. J. of Clinical Oncology, 18(6), 1187-92.
  11. Potters, L., Cha, C., Ashley, R., Yamada, J., et al. (2000). The Role of External Beam Irradiation in Patients Undergoing Prostate Brachytherapy. Urologic Oncology, 5, 112-17.
  12. Potters, L., Wang, Z.H., Yamada, Y. (2000). A nomogram to compensate for intraoperative prostate edema during transperineal brachytherapy. Tech Urol, 6, 99-103.
  13. Potters, L. (2000). Permanent Prostate Brachytherapy: Lessons Learned, Lessons to Learn. Oncology, 14, 981-91.
  14. Gelblum, D.Y., Potters, L. (2000). Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Rad Onc Bio Phys, 48, 119-24.
  15. Kattan, M.W., Fearn, P.A., Leibel, S., Potters, L. (2000). The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Rad Onc Bio Phys, 48, 1469-74.
  16. Perez, C.A., Beyer, D.C., Blasko, J.C., Forman, J.D., et al. (2000). Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1449-72, 1449.
  17. Roach, M., III, Blasko, J.C., Perez, C.A., Beyer, D.C., et al. (2000).Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1441-8,1441.
  18. Perez, C.A., Beyer, D.C., Blasko, J.C., Forman, J.D., et al. (2000). Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1419-39,1419.
  19. Lee, W.R., Pollack, A., Perez, C.A., Beyer, D.C., et al. (2000). Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1413-8,1413.
  20. Pollack, A., Paryani, S.B., Hussey, D., Perez, C.A., et al. (2000). Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1401-12, 1401.
  21. Potters, L., Perez, C.A., Beyer, D.C., Blasko, J.C., et al. (2000). Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1383-400, 1383.
  22. Forman, J.D., Lee, W.R., Roach, M. III, Perez, C.A., et al. (2000). Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl, 1373-82, 1373.
  23. Wang, X.H., Potters, L. (2001). A theoretical derivation of the nomograms for permanent prostate brachytherapy. Med Phys, 28, 683-7.
  24. Potters, L., Cao, Y., Calugaru, E., Torre, T., et al. (2001). A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. J Rad Oncol Bio Phys, 50(3), 605-614.
  25. Potters, L., Tore, T., Fearn, P., Leibel, S. (2001). Potency following permanent prostate brachytherapy for localized prostate cancer. Int. J. Rad Oncol Bio Phys, 50 (5), 1235-42.
  26. Kattan, M., Potters, L., Blasko, J., Beyer, D., et al. (2001). A pretreatment nomogram for predicting recurrence-free survival following permanent prostate brachytherapy in prostate cancer. Urology, 58(3), 393-9.
  27. Potters, L., Fearn, P., Kattan, M.W. (2002). The role of external radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer: a matched pair analysis. Prostate Cancer and Prostatic Diseases, 5, 47-53.
  28. Potters, L., Fearn, P., Kattan, M.W. (2002). External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer, Brachytherapy, 1, 36-41.
  29. Lee, L., Barnswell, C., Torre, T., Fearn, P., et al. (2002). Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched pair analyses. Int. J Rad Oncol Bio Phys, 53, 282-9.
  30. Potters, L., Purazzella, R., Brustein, S., Fearn, P., et al. (2002). A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate cancer. Cancer, 95, 1451-6.
  31. Potters, L. (2002). Nomograms for clinically localized prostate cancer: part II, radiation therapy. Sem in Uro Oncol, 20, 131-40.
  32. Yamada, J., Potters, L., Zaider, M., Cohen, G., et al. The impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer optimized and preimplant planning techniques. Am J Clinical Onc, 26(5), 130-5.
  33. Potters, L., Huang, D., Fearn, P., Kattan, M.W. (2003). The effect of isotope selection on the PSA response in patients treated with permanent prostate brachytherapy. Brachytherapy, 2, 26-31.
  34. Potters, L., Purrazzella, R., Brustein, S., Fearn, P., et al. (2003). Prognostic significance of gleason grade in patients treated with permanent prostate brachytherapy, Int J Rad Oncol Bio Phys, 56(3), 749-54.
  35. Potters, L., Kattan, M.W., Fearn, P. (2003). A chronological database to support outcomes research in prostate cancer. Int J Rad Oncol Bio Phys, 56 (5), 1252-8.
  36. Potters, L., Calguaru, E., Thorenson, K., Jackson, T., et al. (2003). Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy, 2(3), 172-80.
  37. Potters, L. Permanent prostate brachytherapy in patients with clinically localized prostate cancer. (2003). Clinical Oncology, 15, 301-15.
  38. Potters, L., Huang, D., Calugaru, E., Fearn, P. (2003). The importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology, 62(6),1073-7.
  39. Kupelian, P.A., Potters, L., Khuntia, D., Ciezki J.P., et al. (2004). Radiacal prostatectomy, external beam radiotherapy (<72Gy), external beam radiotherapy (>72 Gy), permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1/T2 prostate cancer. Int J Rad Oncol Bio Phys, 58, 25-33.
  40. Potters L, Kattan MW, Reddy CA, Klein EA, Ciezki JP, Kupleian PA. Monotherapy for Stage T1/T2 Prostate Cancer: Radical Prostatectomy, External Beam Radiotherapy, or Permanent Prostate Brachytherapy. Radioth and Onc  2004, 71(1) 29-33.
  41. Potters, L., Steinberg, M., Rose, C., Timmerman, R., et al. (2004). American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotatic body radiation therapy. Int J Rad Oncol Bio Phys, 60(4),1016-17.
  42. Crook, J., Potters, L., Stock, R., Zelefsky, M. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. (2005). An American Brachytherapy Society Consensus Statement. Brachytherapy, 4(3) 186-94.
  43. Potters, L., Morgenstern, C., Calugaru, E., Huang, Y., et al. (2005). Twelve year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J of Urology, 173, 1562-6.
  44. Potters, L., Timmerman, R., Larson, D. (2005). Stereotatic body radiation therapy. J of Am College of Radiol, 2, 676-80.
  45. Acher, P.L., Morris, S.L., Popert, R.J.M.P., Perry, M.J.A., et al. (2006). Permanent prostate brachytherapy: a century of technical evolution. Prostate Cancer Prostatic Dis, 9(3), 215-20.
  46. Williams, S.G., Pickles, T., Kestin, L., Potters, L., et al. (2006). Multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculations systems. In press. Int J Rad Oncol Bio Phys, 65(5), 1494-1500.
  47. Potters, L., Calugaru, E., Jassal, A., Presser, J. (2006). Is there a role for post-implant dosimetry following real-time dynamic permanent prostate brachytherapy? In press. Int J Rad Oncol Bio Phys, 65(4),1014-19.
  48. Acher, P., Popert, R., Nichol, J., Potters, L., et al. Permanent prostate brachytherapy: dosimetric results and analysis of a learning curve with a dynamic-feedback technique. (2006). Int J Rad Oncol Bio Phys, 65(3), 694-8.
  49. Dillehay, G.L., Ellerbroek, N.A., Balon, H., Brill, D.R., et al. (2006). Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Int J Rad Oncol Bio Phys, 64(5), 1299-1307.
  50. Kuban, D.A., Levy, L.B., Potters, L., Beyer, D.C., et al. (2006). Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Rad Oncol Bio Phys, 65(5), 1487-93.
  51. Zelefsky, M.J., Kuban, D.A, Levy, L.B., Potters, L., et al. (2007). Multi-Institutional analysis of long term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Rad Oncol Bio Phys, 67(2), 327-33.
  52. Scardino, P., Abenhaim, L., Rossignol, M., Carroll, P., et al. (2007). The treatment f localized prostate cancer and the focal lesion paradigm: review and recommendations by an international task force. J of Urology (supplementary publication).
  53. Acher, P.L., Popert, R., Morris, S.L., Potters, L., et al. (2007).Dynamic dose-feedback prostate brachytherapy (LDR) in patients with large prostates and/or planned pre-implant transurethral surgery. British J Uro.
  54. D'Ambrosio, D.J., Pollack, A., Harris, E.R., Price, Jr. R.A., Verhey, L.J., et al. Target dose escalation and normal tissue protection in modern external beam radiation therapy (EBRT) for localized cancer of the prostate: a critical review and analysis of the literature. Submitted IJROB 2007.

Book Chapters, Editorials and Letters

    1. Aziz, H., Rosenthal, J.C., Potters, L., Nuthakki, M. et al. (1991). Non-small cell carcinoma of the lung. In M. Rotman and C.J. Rosenthal (Eds.), Clinical applications of continuous infusion chemotherapy and concomitant radiation therapy, 2nd Edition. Germany: Springer Verlag, 223-8.
    2. Rotman, M., Aziz, H., Potters, L., Choi, K. (1991). Treatment of advanced carcinoma of the bladder with concomitant 5-Fu infusion and radiation. In M. Rotman and C.J. Rosenthal (Eds.), Clinical applications of continuous infusion chemotherapy and concomitant radiation therapy, 2nd Edition. Germany: Springer Verlag, 167-74.
    3. Potters, L., Freeman, K. (1999). Prostatectomy, external beam radiation therapy or brachytherapy for localized prostate cancer. [Letter] JAMA, 281,1584.
    4. Bosworth, J., Waldbaum, R., Potters, L. (2000). Brachytherapy for prostate cancer. In: H. Lepor (Ed.), Prostatic diseases. Philadelphia: W. B. Saunders Co., 451-560.
    5. Potters, L. (2000). Iodine-125 vs. palladium-103: long-term complications [Letter]. Radiat Oncolol Invest, 90, 110-11.
    6. Torre, T., Potters, L. (2001). Modern review of radiation for breast cancer [Editorial]. Oncology, 15, 480-3.
    7. Potters, L., Kattan, M.W., Scardino, P. (2001). Combined modality staging for clinically localized adenocarcinoma of the prostate. [Editorial] Oncology, 15, 1065-75.
    8. Potters, L., Kattan, M.W. (2003). Modifying the ASTRO definition of biochemical failure. [Editorial] J Urology, 169(6), 2158.
    9. Potters, L., Steinberg, M., Wallner, P., Hevisi, J. (2003). How one defines intensity modulated radiation therapy. [Editorial] Int J Rad Oncol Bio Phys, 56(3), 609-10.
    10. Potters, L. The role of external radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. (2004). Basic and advanced techniques in prostate brachytherapy. In: A. Dicker, G. Merrick, et al. (Eds.) London: Martin Dunitz Ltd., 353-61.
    11. Potters, L. (2004). Rectal complications associated with permanent prostate brachytherapy for prostate cancer. Basic and advanced techniques in prostate brachytherapy. In: A. Dicker, G. Merrick, et al. (Eds). London: Martin Dunitz Ltd, 421-6.
    12. Potters, L. (2005). Permanent prostate brachytherapy. In: J.N. Lucas (Ed.) Trends in prostate cancer research. 1st Edition, New York, 99-168.
    13. Kuban, D., Potters, L., Lawton, C. (2007). Chapter 50. Prostate cancer. In: L. Gunderson and J. Tepper (Eds). Clinical radiation oncology, 2nd Edition. Philadelphia: Elsevier Churchill Livingston, 1165-1236.
    14. Abenhaim, L., Carroll, P., Rossignol, M., Higano, T. (In press). Report from the international task force on prostate cancer treatment and the focal lesion paradigm. Whiley Co.
    15. Potters, L. (2007). The art of radiation oncology? Int J of Rad Onc Bio Phys, 68(4), 966-7.

Abstracts (Peer Reviewed Presentations at National or Regional Scientific Meetings)

  1. Choi, K.N., Aziz, H., Potters, L., Stark, R., et al. (1990). Locally advanced paranasal sinus and nasopharyngeal cancers treated with hyperfractionated radiation and concomitant cisplatinum infusion. Proceedings of the meeting of the American Radium Society, 72, 9.
  2. Aziz, H., Austin, J.P., Potters, L., Thelmo, W., et al. (1990). Adverse effect of transurethral resection on survival in prostate carcinoma. Proceedings of the American Radium Society, 72, 38.
  3. Potters, L., Rush, S., Lovecchio, J., Gal, D., et al. (1993). Outcome and prognostic factors of chemosensitized radiation therapy for the treatment of locally advanced cervical cancer. Int J Rad Onc Bio Phy, 27 (supp 1), 289.
  4. Dlugacz, Y., Zenobio, T., Potters, L., Horowitz, R., et al. (1994). The concerns of the patient receiving brachytherapy: a continued quality improvement approach to patient and staff satisfaction. Proceedings of the first international conference on social work in health care, Israel.
  5. Gal, D., Rush, S., Potters, L., Lovecchio, J., et al. (1994). Prognostic indicators after surgery and adjuvant external radiation for clinical stage I endometrial cancer. Proceedings of the UICC meeting, India.
  6. Gal, D., Rush, S., Potters, L., Bosworth, J., et al. (1995). Pelvic control following postoperative external radiation for surgical stage I endometrial cancer. Surgical Gynecologic Oncology.
  7. Potters, L., Waldbaum, R.S., Riley, R., Bosworth, J. (December 1995). Transperineal implantation of the prostate with Pd-103 vs I-125. American Brachytherapy Society, 12, 1-4.
  8. Rush, S., Potters, L., Bosworth, J., Ashley, R., et al. (May 1996). A comparison of brachytherapy with conventional external beam radiation therapy for prostate cancer. Proceedings of the International Brachytherapy Meeting, Tours, France
  9. Potters, L., Rush, S., Ashley, R., Bosworth, J., et al. (1996). A comparison of prostate brachytherapy with conventional external beam radiation for prostate cancer. Proceedings of the New York AUA, Paris.
  10. Potters, L., Ashley, R., Waldbaum, R., Bosworth, J. (October 1996). TURP for patients with grade III urinary symptoms following transperineal implantation of the prostate. Proceedings of the American Society of Therapeutic Radiation Oncology, 36 (Supp 1), 2070.          
  11. Potters, L., Waldbaum, R., Ashley, R., Barbaris, H., et al. (May 1997). Predicting successful treatment of prostate cancer using transperineal implantation. Proceedings of the American Society of Clinical Oncology, 16, 1215.
  12. Potters, L., Bosworth, J., Ashley, R., Barbaris, H., et al. (May 1997). External radiation combined with transperineal prostate implants for high risk localized prostate cancer. Proceedings of the American Brachytherapy Society 19th Annual Meeting, 22.
  13. Potters, L., Cha, C., Bosworth, J., Waldbaum, R., et al. (1998). Results for 579 patients treated with transperineal interstitial prostate implants. Proceedings of the American Radium Society.
  14. Cha, C., Potters, L., Bosworth, J., Steckel, J., et al. (1998).Transperineal interstitial implant with and without pelvic radiation for localized prostate cancer. Proceedings of the American Urologic Society.
  15. Scherr, D., Bosworth, J., Potters, L., Waldbaum, R., et al. (1998). Brachytherapy experience in 405 men treated for localized prostate cancer: initial PSA as predictor of response along with complications of therapy. Proceedings of the 8th International Prostate Cancer Meeting.
  16. Scherr, D., Bosworth, J., Potters, L., Waldbaum, R., et al. (1998). Complications of brachytherapy in 692 men treated for localized prostate cancer. Proceedings of the American Urologic Society.
  17. Wang, X.H., Potters, L. (July 1998). The effects of edema on the dosimetry of prostate seed implant. Proceedings of the Annual AAPM, San Antonio, Texas.
  18. Cha, C., Potters, L., Ashley, R., Waldbaum, R., et al. (1998). Isotope selection for patients undergoing prostate brachytherapy. (Abstract, Int J Rad Onc Bio Phy, 42 [supp 1], 19).
  19. Potters, L., Cha, C., Ashley, R., Barbaris, H., et al. (1998). Is pelvic radiation necessary in patients undergoing prostate brachytherapy? (Abstract, Int J Rad Onc Bio Phy, 42 [supp 1], 2138).
  20. Wang, X., Zhang, J., Potters, L., Ling, C. (1999). Use of Nomogram vs. Pre-planning to determine Seed Activities fro Prostate Seed Implants (Abstract, Medical Physics, 26, 1145).
  21. Cao, Y., Wang, X., Potters, L., Ling, C. (1999). Dosimetric Analysis of Permanent Prostate Implant with I-125 and Pd-103. (Abstract, Medical Physics, 26, 1144).
  22. Gelblum, D., Potters, L., Ashley, R., Waldbaum, R., et al. (1998).Urinary morbidity following ultrasound transperineal prostate seed implantation. (Abstract, Int J Rad Onc Bio Phy, 42 [supp 1], 1023).
  23. Leif, E.P., Wang, X., Cha, C., Potters, L. (1998). Rectal dose in Pd-103 and I-125 permanent prostate implants. (Abstract, Radiology, 209 [supp],157).
  24. Torre, T., Potters, L., Ashley, R., Leibel, S. (1999). Efficacy of neoadjuvant hormone therapy in patients undergoing prostate brachytherapy. (Abstract, American Society of Clinical Oncology,18 [supp], 1211).
  25. Potters, L. (1999). Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. (Abstract, J of Brachytherapy, 145, 45-P).
  26. Lief, E., Hanley, J., Cann, D., Schupak, K., et al. (1999). Dose inhomogeneities for different techniques of permanent prostate implants with I-125 and 103Pd-103 seeds. (Abstract, Int J Rad Onc Bio Phy, 45 [supp 1], 2268).
  27. Yamada, Y., Potters, L., Zelefsky, M., Venkatraman, E., et al. (1999). A prospective analysis using real-time intraoperative planning to account for porstatic edema during permanent prostate brachytherapy. (Abstract, Clin Invest Med, 22, 4, S36).
  28. Yamada, Y., Potters, L., Venkatramen, E., Zelefsky. (1999). A prospective evaluation of intraoperative prostatic edema during prostate brachytherapy and its effect upon the postimplant dosimetry of patients planned with preoperative or real time intraoperative treatment planning. (Abstract, Radiology, 108, [33]213).
  29. Kattan, M.W., Blasko, J.C., Beyer, D.C., Cavanaugh, W., et al. (2000). A multi-institutional nomogram for predicting the outcome of ultrasound guided transperineal brachytherapy in prostate cancer. (Abstract, J Urology, 163[4], 1441).
  30. Gelblum, D.Y., Potters, L. (2000). Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Proceedings of ASCO, 19, 1421.
  31. Kattan, M.W., Blasko, J.C., Beyer, D.C., Cavanaugh, W., et al. (2000). A multi-institutional nomogram for predicting the outcome of ultrasound guided transperineal brachytherapy in prostate cancer. (Abstract, Radiotherapy and Onc, 55 [supp1], 65).
  32. Potters, L., Cao, Y., Torre, T., Calugaru, E., et al. (2000). Comprehensive analysis of dosimetry from 755 patients undergoing transperineal interstitial permanent prostate brachytherapy. (Abstract, Radiotherapy and Onc, 55 [supp1], 66).
  33. Ciao, Y., Wang, X.H., Potters, L. (2000). Prostate cancer with interstitial seed implants. The characterization of dosimetry parameters and its correlation to biochemical control in treating early stage prostate cancer with interstitial implants (Abstract, Medical Physics, 27, 1433).
  34. Calugaru, E., Wand, X.H., Cao, Y., Potters, L. (2000). Statistical analysis of a new calibration technique for prostate seed implant sources. (Abstract, Medical Physics, 27, 1436).
  35. Torre, T., Potters, L. Biopsy location and biochemical relapse after permanent prostate brachytherapy. Proceedings of the 98th Annual Meeting Symposium, NY Section-AUA.
  36. Potters, L., Kattan, M., Fearn, P., Leibel, S., et al. (2001). The role of external radiotherapy and permanent prostate brachytherapy in low and intermediate risk patients with localized prostate cancer. (Abstract, J Urology, 165[5], 1330).
  37. Potters, L., Torre, T., Fearn, P., Leibel, S., et al. (2001). Potency following permanent prostate brachytherapy for localized prostate cancer. (Abstract, J Urology, 165[5], 1441).
  38. Kattan, M., Fearn, P., Leibel, S., Potters, L. (2001). A modified version of the ASTRO definition for biochemical recurrence following radiation therapy. (Abstract, J Urology, 165[5], 1323).
  39. Torre, T., Potters, L., Wang, X.H., Calugaru, E., et al. (2001). Biopsy location and biochemica relapse after permanent prostate brachytherapy. J Urology, 165 (5),1450.
  40. Wang, H.X., Calurgaru, E., Torre, T., Potters, L. (2001). A statistical analysis of seed migration following permanent prostate brachytherapy. (Abstract, Medical Physics, 28[6], C-24.)
  41. Potters, L., Torre, T., Barnswell, C., Fearn, P., et al. (2001). Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: a matched pair analysis. (Abstract, Int J Rad Onc Bio Phy, 51[supp 1], 2140).
  42. Potters, L., Fearn, P., Kattan, M. (2001). The role of external radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer: a matched pair analysis. (Abstract, Int J Rad Onc Bio Phy 51 [supp 1], 1044).
  43. Potters, L., Fearn, P., Kattan, M.W. (2001). A comprehensive and novel predicative modeling technique using detailed pathology factors in men with localized prostate cancer. (Abstract, Int J Rad Onc Bio Phy, 51 [supp 1], 304).
  44. Wang, X.H., Calugaru, E., Potters, L., Grob, B.M., et al. (2001). The uncertainty in determining the post-implant CT-scan dosimetry in patients treated with permanent prostate brachytherapy. (Abstract, Radiology, 246).
  45. Potters, L., Kattan, M.W., Reddy, C.A., Klein, E.A., et al. (2002). Monotherapy for stage T1/T2 prostate cancer: radiacal prostatectomy, external beam radiotherapy, or permanent prostate brachytherapy. (Abstract, Int J Rad Onc Bio Phy, 54 [supp 1], 9).
  46. Kupelian, P.A., Potters, L., Ciezki, J.P., Reddy, C.A., et al. (2002). Radical prostatectomy, external beam radiotherapy (<72Gy), external beam radiotherapy (>72 Gy), permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1/T2 prostate cancer. (Abstract, Int J Rad Onc Bio Phy, 54 [supp 1], 61).
  47. Calugaru, E., Huang, D.Y., Coa, Y., Potters, L. (2003). Acceptance testing and monthly QA of Variseed brachytherapy software. AAPM.
  48. Potters, L., Kattan, M., Huang, D., Fearn, P., et al. (2003).The importance of implant dosimetry for patients undergoing prostate brachytherapy. (Abstract, J Urology, 169[4], 1846).
  49. Calugaru, E., Huang, D., Potters, L. (2003). Acceptance testing and monthly QA of Variseed brachytherapy. (Abstract, Med Phys, 30 [PO-T-16], 1466).
  50. Calugaru, E., Potters, L., Lee, L., Huang, Y. (2004). A quick double check method for prostate brachytherapy. (Abstract, Med Phys).
  51. Potters, L., Morgenstern, C., Mullen, E.E., Fearn, P., et al. (2004). Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer. Int J Rad Onc Bio Phy, 60(supp 1), 88.
  52. Williams, S., Kestin, L., Potters, L. Fearn, P., et al. (2002). How reliable are electronic biochemical failure algorithms? An examination of the variability of results from four centres. Int J Rad Onc Bio Phy, 63(supp 1), 1089.
  53. Kuban, D., Levy, L., Potters, L., et al. (2005). Comparison of PSA failure definitions for prostate implant. Int J Rad Onc Bio Phy, 63(supp 1), 57.
  54. Potters, L., Calugaru, E., Jassal, A., Presser, J. (2002). Is there a role for post-implant dosimetry following real-time dynamic permanent prostate brachytherapy? Int J Rad Onc Bio Phy, 63(supp 1), 60.
  55. Zelefsy, M.J., Kuban, D.A., Levy, L.B., Potters, L., et al. (2005). Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with permanent brachytherapy. Int J Rad Onc Bio Phy, 63 (supp 1), 56.
  56. Archer, P., Popert, R., Potters, L., Nichol, S., et al. Should patients with large prostates be offered permanent prostate brachytherapy for localized prostate cancer. Proceedings of the 2006 Prostate Cancer Symposium. (Abstract No. 100, p. 143).
  57. Archer, P., Popert, R., Nichol, S., Potters, L. et al. (2006). Permanent prostate brachytherapy: dosimetry results and analysis of a learning curve with a dynamic dose-feedback technique. Proceedings of the Prostate Cancer Symposium. (Abstract No. 101, p. 144).
  58. Stone, N.N., Potters, L., Davis, B.J., Ciezki, J.P., et al. (2006). Customized dose prescription for prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Rad Onc Bio Phys, (66), 3 (supp), S11-12.
  59. Elshaikh, M.A., Kuban, D., Levy, L., Potters, L., et al. (2006). Long-term multi-institutional outcome and biochemical failure definition analysis of combined permanent brachytherapy with external beam radiation for prostate cancer. Int J Rad Onc Bio Phys, (66), 3 (supp), S57-8.
  60. Kattan, M.W., Stock, R.G., Ciezki, J.P., Davis, B.J., et al. (2006). An updated 9-year preoperative nomogram predicting for prostate cancer recurrence after permanent prostate brachytherapy. Int J Rad Onc Bio Phys, (66), 3 (supp), S59.
  61. Horwitz, E.M., Levy, L.B., Martinez, A.A., Potters, et al. (2006). The post-treatment PSA bounce for prostate cancer patients treated with external beam RT or permanent brachytherapy alone is not biochemically or clinically significant: a multi-institutional pooled analysis of more than 7,500 patients. Int J Rad Onc Bio Phys (66), 3 (supp), S205.
  62. Potters, L., Stock, R.G., Ciezki, J.P., Davis, B.J., et all. (2006). Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy. Int J Rad Onc Bio Phys, (66) 3 (supp), S329.
  63. Stone, N.N., Potters, L., Davis, B.J., Ciezki, J.P., et al. (2007). Multicenter analysis of outcomes in patients treated with permanent prostate brachytherapy: effect of PSA failure definition and dose on biochemical defined relapse. J of Urology, 144(4), 1763, 586.



Search Articles

Search our archives for print and web articles.

Go >